1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Global Markets for Infectious Disease Treatments

Global Markets for Infectious Disease Treatments

  • January 2016
  • -
  • BCC Research
  • -
  • 197 pages

This BCC Research report provides the reader with a detailed analysis of the global infectious disease market, with emphasis on seven major infectious diseases (i.e., human immunodeficiency virus/acquired immunodeficiency virus [HIV/AIDS]; hepatitis A, B, C; malaria, rotavirus/diarrhea; measles; pneumonia; and tuberculosis [TB]). Includes forecasts from 2016-2021.

Use this report to:

Assess the current state of infectious diseases on a global basis.
Identify the driving factors for demand of new diagnostic and pharmaceutical products.
Estimate current and future market sizes for diagnostic, vaccine, and pharmaceutical infectious disease products.
Estimate the current global supply-and-demand scenario, by disease type and geographical region.

Highlights

The global market for infectious disease diagnostic, vaccine, and pharmaceutical treatment products reached $108.4 billion in 2015. The market should reach $126.2 billion in 2016 and $183.2 billion in 2021, demonstrating a compound annual growth rate (CAGR) of 7.7% from 2016 to 2021.
Pharmaceutical treatments make up the fastest-growing segment of the market totaling $65.4 billion in 2015 and an estimated $78.3 billion in 2016. The market segment should grow at a CAGR of 8.8%, leading to a projected total of $119.3 billion by 2021.
The vaccine market for infectious diseases totaled $25.2 billion in 2015. The market should reach $28.5 billion in 2016 and $39.7 billion in 2021, a CAGR of 6.8%.

STUDY GOALS AND OBJECTIVES

Infectious diseases are one of the major causes of global morbidity and mortality. Viral, bacterial, parasitic and fungal diseases have plagued humankind for centuries, and our attempts to control these diseases have met with great success. Diseases that were once death sentences are now either virtually eliminated or have become chronic, manageable diseases.
However, as with every ongoing story, microbes have transformed themselves to outwit current medications, and the battle to rid humans of the most virulent of diseases continues. With the constant combining and reinvention of microbes comes an urgent need for improved antibiotic and viral medications to sustain the progress made in addressing the most aggressive of infectious diseases.
Under these circumstances, there is need for a current and comprehensive report on infectious diseases covering diagnosis, treatment, demand trends, opportunities and emerging technologies.
This study gives a clear, quantitative picture of the supply-and-demand scenario, and it highlights the echnological and investment opportunities in the field.


Table Of Contents

Global Markets for Infectious Disease Treatments

CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 3
INTENDED AUDIENCE 3
METHODOLOGIES AND INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
SUMMARY TABLE GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC,
VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC,
VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%) 7
CHAPTER 3 OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS,
VACCINES AND TREATMENT 10
TOP GLOBAL CAUSES OF DEATH 10
TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME
LEVEL, 2012* (%) 11
MAJOR INFECTIOUS DISEASES 11
TABLE 2 SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER
OF CASES, TREATMENT OPTIONS) 12
HISTORICAL IMPACT OF INFECTIOUS DISEASES 12
LEADING CAUSES OF GLOBAL DEATHS 13
Transmission of Infectious Diseases 13
LINKING INFECTIOUS DISEASE TO CANCER 13
TREATMENTS FOR INFECTIOUS DISEASES 13
PREVENTION 13
VACCINATION 14
WHO Global Vaccination Action Plan 14
FIGURE 1 GLOBAL IMMUNIZATION COVERAGE, 2014 (%) 14
Challenges to Meet WHO Guidelines 15
GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET 16
TYPES OF DIAGNOSTIC TESTING 16
FLUORESCENT IMMUNOASSAY (FIA) 16
Direct Fluorescent Antibody Testing (FA) 17
Indirect Fluorescent Antibody Testing (IFA) 17
ENZYME IMMUNOASSAY (EIA) 17
Basic EIA 17
Enzyme-Linked Immunosorbent Assay (ELISA) 18
GENE PROBE ANALYSIS 18
Polymerase Chain Reaction Amplification (PCR) 18
Nucleic Acid Amplification Test (NAT) 19
Transcription-Mediated Amplification (TMA) 19
Nucleic Acid Sequence-Based Amplification (NASBA) 19
GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 20
TABLE 3 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC
PRODUCTS, THROUGH 2021 ($ MILLIONS) 20
GLOBAL INFECTIOUS DISEASE VACCINE MARKET 20
TABLE 4 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS,
THROUGH 2021 ($ MILLIONS) 21
GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET 21
TABLE 5 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 21
VACCINE OPPORTUNITIES 21
CHILDHOOD DISEASES 21
GLOBAL HUMANITARIAN AGENCIES 22
PHARMACEUTICAL OPPORTUNITIES 22
THE EMERGENCE OF GENE THERAPY 22
MERGERS AND ACQUISITIONS 23
TABLE 6 SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 ($ MILLIONS) 23
CHAPTER 4 VACCINES - THE PRESENT AND THE FUTURE 26
VACCINES AND PATENTS 26
MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES 26
TABLE 7 GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINE PRODUCTS,
THROUGH 2021 ($ MILLIONS) 27
TABLE 8 GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES BY DISEASE,
THROUGH 2021 ($ MILLIONS) 27
TYPES OF VACCINES 27
LIVE ATTENUATED VACCINE 27
INACTIVATED VACCINE 28
Acellular/Subunit Vaccines 28
IMMUNITY 28
INNATE IMMUNITY 28
ACQUIRED IMMUNITY 28
The Activity of T Cells 29
Acquired Immunity - Cell-Mediated Response 29
LASTING IMMUNITY 30
VIRAL DISEASES PREVENTED BY VACCINE 30
TABLE 9 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 30
BACTERIAL DISEASES PREVENTED BY VACCINE 31
TABLE 10 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 31
VACCINATION SCHEDULES FOR CHILDREN IN THE U.S. 32
TABLE 11 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS IN
THE U.S. 32
TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS, TO 4
YEARS TO 6 YEARS IN THE U.S. 32
TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7
YEARS TO 18 YEARS IN THE U.S. 33
CONCERNS REGARDING VACCINATION IN CHILDHOOD 33
NUMBER OF INOCULATIONS 33
RECOGNIZING IMMUNE RESPONSE 34
IMMUNIZATION AND WEAKENED OR ALTERED IMMUNE SYSTEMS 34
HEPATITIS B VACCINATIONS THROUGH WHO GUIDELINES 34
VACCINE PRODUCTION 34
FIGURE 2 VACCINE MANUFACTURING PROCESS 35
VACCINE MANUFACTURERS 35
FIGURE 3 GLOBAL VACCINE MANUFACTURING MARKET, 2014 (%) 35
CHANGES IN MANUFACTURING LANDSCAPE 36
TOP-SELLING VACCINES OF 2014 37
TABLE 14 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION,
MANUFACTURER AND REVENUE, 2014 37
GLOBAL VACCINATION EFFORTS 37
REGIONAL ANALYSIS 38
TABLE 15 REGIONAL MARKETS FOR VACCINES, THROUGH 2021 ($ MILLIONS) 38
FIGURE 4 REGIONAL MARKET SHARE FOR VACCINES, 2016 AND 2021 (%) 38
THE AMERICAS 39
TABLE 16 AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS) 40
EMRA 40
TABLE 17 EMRA MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS) 40
ASIA 41
TABLE 18 ASIAN MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS) 41
TRENDS IN VACCINE DEVELOPMENT 42
ADJUVANT DEVELOPMENT 42
COMBINATION VACCINES 42
INHALED OR INTRANASAL VACCINE ADMINISTRATION 43
NEED FOR RAPID RESPONSE TIMES 43
Real-Time Detection 43
CHAPTER 5 VIRAL INFECTIOUS DISEASES 46
GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS 46
TABLE 19 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS) 46
PATENT PROTECTION 47
TABLE 20 PATENT EXPIRY BY PRODUCT, INDICATION, MANUFACTURER AND DATE
OF PATENT EXPIRY 47
HEPATITIS B AND C 48
MARKET FOR HBV AND HCV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS 48
TABLE 21 GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 48
DIAGNOSIS 48
TABLE 22 GLOBAL MARKET SHARE FOR HEPATITIS B AND C DIAGNOSTIC PRODUCT
BY TYPE OF TEST AND REVENUES, 2015 ($ MILLIONS/%) 49
TABLE 23 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND
C BY BRAND NAME AND MANUFACTURER, 2015 49
Automated Infectious Disease Testing for Hepatitis 51
TREATMENT MARKET 51
TABLE 24 GLOBAL MARKET FOR HEPATITIS B AND C TREATMENT MANUFACTURER
MARKET STANDING BY REVENUES, 2015 ($ MILLIONS/RANK) 51
FIGURE 5 GLOBAL MARKET SHARE FOR TOP PHARMACEUTICAL MANUFACTURERS
IN THE HEPATITIS MARKET, 2015 (%) 52
TABLE 25 PHARMACEUTICALS FOR THE TREATMENT OF HEPATITIS B AND C, 2015 53
NEWEST PHARMACEUTICALS TO TREAT HBV AND HCV 54
Additional Competitor 54
MARKET FOR DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS TO TREAT
HBV AND HCV 54
TABLE 26 GLOBAL MARKET FOR HBV AND HCV PHARMACEUTICALS, THROUGH
2021 ($ MILLIONS) 54
RISK FACTORS 54
GEOGRAPHICAL DISTRIBUTION 55
HERPES SIMPLEX VIRUS 55
TABLE 27 GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 55
INCIDENCE 56
DIAGNOSIS 56
TABLE 28 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HSV BY BRAND
NAME, TYPE AND MANUFACTURER, 2015 56
TREATMENT 57
TABLE 29 DRUGS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND
MANUFACTURER 57
HIV/AIDS 57
TABLE 30 GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 58
RISK FACTORS 58
INCIDENCE/MORTALITY 59
ANTIRETROVIRAL THERAPY (ART) 59
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) 59
TABLE 31 COMBINATION DRUGS APPROVED FOR HAART 59
HAART Failure 61
Mega-HAART 61
"TREATMENT FOR ALL" WHO PROGRAM 61
COUNT Pre-Exposure Prophylaxis 61
CLINICAL TRIALS FOR HIV VACCINE AND MEDICATIONS 62
HUMAN PAPILLOMAVIRUS 62
TABLE 32 GLOBAL MARKET FOR HPV DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 63
HPV AND CANCER 63
TABLE 33 CANCERS LINKED TO HPV INFECTION, BY TYPE AND PERCENT OF
FREQUENCY 63
INCIDENCE 63
SYMPTOMS 64
DIAGNOSIS 64
TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND
NAME, TYPE AND MANUFACTURER, 2015 64
TREATMENT 65
TABLE 35 DRUGS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME AND
MANUFACTURER 65
INFLUENZA A AND B 65
VACCINE 65
TREATMENT 66
CHILDHOOD DISEASES 66
MEASLES 66
MUMPS 66
POLIO 67
VIRAL PNEUMONIA 67
Treatment 67
ROTAVIRUS 67
DEHYDRATION 68
ZINC 68
RSV 68
SYMPTOMS 68
DIAGNOSTIC PRODUCTS 69
TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND
TYPE, 2015 69
VIRAL DIAGNOSTIC PRODUCTS 69
TABLE 37 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC
PRODUCTS, THROUGH 2021 ($ MILLIONS) 70
VIRAL PHARMACEUTICAL PRODUCTS 70
TABLE 38 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 70
REGIONAL ANALYSIS 71
TABLE 39 REGIONAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS) 71
FIGURE 6 REGIONAL MARKET SHARE FOR VIRAL DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%) 72
TABLE 40 REGIONAL MARKET FOR VIRAL DIAGNOSTIC PRODUCTS, THROUGH 2021
($ MILLIONS) 73
TABLE 41 REGIONAL MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS, THROUGH
2021 ($ MILLIONS) 73
AMERICAS 73
Hepatitis B in the U.S. 73
Hepatitis C in the U.S. 74
Market for Viral Infectious Disease Products in the Americas 74
TABLE 42 AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC
PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS) 74
TABLE 43 AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL
PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS) 74
EMRA 75
Hepatitis C 75
Hepatitis in Africa 75
Hepatitis in Russia, Eurasia 76
Russian Pharmaceutical Regulations 76
Market for Viral Infectious Disease Diagnostic Products 76
TABLE 44 EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
BY REGION, THROUGH 2021 ($ MILLIONS) 76
TABLE 45 EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL
PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS) 77
ASIA 77
Hepatitis in Asian Region 77
TABLE 46 CURRENTLY USED HEPATITIS DRUGS IN THE SOUTHEAST ASIAN REGION,
BY PERCENT OF USE, 2012* 78
Hepatitis in Japan 78
Hepatitis in China 78
Hepatitis in India 79
HIV in Japan 79
HIV in India 79
HIV in China 80
TABLE 47 ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
BY REGION, THROUGH 2021 ($ MILLIONS) 80
TABLE 48 ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL
PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS) 81
CHAPTER 6 BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF ANTIBIOTIC
RESISTANCE 83
NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES 83
TABLE 49 NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES 83
MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS 83
TABLE 50 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC
AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS) 84
MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS 84
TABLE 51 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS,
THROUGH 2021 ($ MILLIONS) 84
MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS 85
TABLE 52 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES
PHARMACEUTICALS, THROUGH 2021 ($ MILLIONS) 85
NOTABLE BACTERIAL DISEASES 86
SEXUALLY TRANSMITTED DISEASES 86
Chlamydia 86
INCIDENCE 86
DIAGNOSTIC PROCEDURES 86
TABLE 53 CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND
MANUFACTURER, 2015 87
TREATMENTS 88
TABLE 54 CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA 88
Gonorrhea 89
Diagnostic Product Market 89
TABLE 55 GONORRHEA DIAGNOSTIC PRODUCT AND MANUFACTURERS 89
Treatment Market 90
TABLE 56 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS 90
Syphilis 90
TABLE 57 STAGES OF SYPHILIS 91
Risk Factors 91
Incidence 91
Diagnostic Products 92
TABLE 58 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY
BRAND NAME, TYPE AND MANUFACTURER, 2012 92
TREATMENTS 93
BACTERIAL PNEUMONIA 93
Treatment 93
CORYNEBACTERIUM DIPHTHERIAE, CLOSTRIDIUM TETANI, BORDETELLA
PERTUSSIS 93
Diphtheria 93
Tetanus 93
Pertussis 94
MENINGITIS 94
MYCOBACTERIUM TUBERCULOSIS (TB) 94
TABLE 59 GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 95
Epidemiology of TB 95
Geographic Prevalence 96
TABLE 60 GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS) 96
ANTIBIOTIC DEVELOPMENT 96
TABLE 61 ANTIBIOTICS: YEAR OF INTRODUCTION, YEAR OF RESISTANCE
OBSERVED, MODE OF ACTION AND TARGET SPECIES 97
ANTIBIOTIC RESISTANCE 98
MECHANISMS OF RESISTANCE 98
METHODS OF RESISTANCE 99
Beta-Lactamase Production 99
Importing Resistance from Other Organisms 100
Examples of Antibiotic-Resistant Bacteria 100
Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness 101
Antibiotic Discharge 101
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE 101
Failure to Finish Antibiotic Courses 101
Antibiotic Overuse 101
Agricultural Practices 102
TABLE 62 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY
DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009* (POUNDS/%) 103
Patient Pressure 103
RESISTANCE BY CLASS OF ANTIBIOTIC 103
TABLE 63 ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 104
INCIDENCES OF ANTIBIOTIC RESISTANCE 104
ANTIBIOTIC RESISTANCE IN EUROPE 104
ANTIBIOTIC RESISTANCE IN THE U.S. 104
MAJOR ANTIBIOTIC-RESISTANT ORGANISMS 104
VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) 105
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 105
CLOSTRIDIUM DIFFICILE (C. DIFFICILE) 105
REGIONAL ANALYSIS 106
TABLE 64 REGIONAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 106
FIGURE 7 REGIONAL MARKET SHARE FOR BACTERIAL INFECTIOUS DISEASES
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%) 106
THE AMERICAS 107
STDs in the U.S. 107
TABLE 65 AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 108
Bacterial Infection Diagnostic Product Market in the Americas 108
TABLE 66 AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTIC
PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS) 108
Bacterial Infection Pharmaceutical Market in the Americas 109
TABLE 67 AMERICAS MARKET FOR BACTERIAL INFECTION PHARMACEUTICAL
PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS) 109
EMRA (EUROPE, MIDDLE EAST, RUSSIA, AFRICA) 109
TABLE 68 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS) 110
Bacterial Infectious Diseases Diagnostic Market in EMRA 110
TABLE 69 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC
PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS) 110
Bacterial Infectious Diseases Pharmaceutical Product Market in EMRA 110
TABLE 70 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL
PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS) 111
ASIA 111
TABLE 71 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS) 111
Bacterial Infectious Diseases Diagnostic Product Market in Asia 112
TABLE 72 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC
PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS) 112
Bacterial Infectious Diseases Pharmaceutical Product Market in Asia 112
TABLE 73 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES
PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS) 113
CHAPTER 7 PARASITIC INFECTIOUS DISEASES 115
NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES 115
TABLE 74 NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES 115
CLIMATE CHANGE AND VECTOR-BORNE DISEASES 116
MALARIA 116
INCIDENCES OF MALARIA 116
Global Risk for Malaria 117
CAUSES OF MALARIA 117
Symptoms of Malaria 117
GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL
TREATMENTS 117
TABLE 75 GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 117
DIAGNOSIS OF MALARIA 118
TABLE 76 GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH
2021 ($ MILLIONS) 118
TREATMENT OF MALARIA 118
TABLE 77 CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH
TREATMENT AND MANUFACTURER, 2015 118
TABLE 78 GLOBAL MARKET FOR MALARIAL PHARMACEUTICAL PRODUCTS,
THROUGH 2021 ($ MILLIONS) 119
REGIONAL ANALYSIS 119
TABLE 79 REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 120
FIGURE 8 REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, 2016 AND 2021 (%) 120
THE AMERICAS 121
TABLE 80 AMERICAS MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 121
Malarial Diagnostic Product Market in the Americas 121
TABLE 81 AMERICAS MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION,
THROUGH 2021 ($ MILLIONS) 122
Malarial Pharmaceutical Market in the Americas 122
TABLE 82 AMERICAS MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY
REGION, THROUGH 2021 ($ MILLIONS) 122
EMRA 122
TABLE 83 EMRA MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 122
Malarial Diagnostic Product Market in EMRA 123
TABLE 84 EMRA MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION,
THROUGH 2021 ($ MILLIONS) 123
Malarial Pharmaceutical Product Market in the EMRA 123
TABLE 85 EMRA MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION,
THROUGH 2021 ($ MILLIONS) 123
ASIA 124
TABLE 86 ASIAN MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, THROUGH 2021 ($ MILLIONS) 124
TABLE 87 ASIAN MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION,
THROUGH 2021 ($ MILLIONS) 124
TABLE 88 ASIAN MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION,
THROUGH 2021 ($ MILLIONS) 125
TABLE 89 CURRENT AND PARASITIC PHARMACEUTICALS WITH TRADE NAME,
GENERIC NAME, MANUFACTURER AND AREA OF TREATMENT, 2014 125
MARKET FOR ANTIPARASITIC PHARMACEUTICALS 126
OPPORTUNITIES IN THE MALARIAL DISEASE MARKET 126
DIAGNOSTIC TESTING 126
CHAPTER 8 EMERGING TECHNOLOGY AND PHARMACEUTICALS 128
GLAXOSMITHKLINE/NOVARTIS TRANSACTION 128
HEPATITIS C 128
TABLE 90 FDA-APPROVED PHARMACEUTICALS TO TREAT HCV, 2011-2015 128
TABLE 91 PHARMACEUTICALS IN CLINICAL TRIALS FOR HCV, 2015 129
FIGURE 9 RESEARCH LANDSCAPE FOR HBV PHARMACEUTICALS BY TYPE, 2015 (%) 130
DENGUE VIRUS VACCINE 130
MALARIA 131
TABLE 92 PHASE II and III PIPELINE FOR MALARIAL TREATMENTS, 2015 131
BASILEA PHARMACEUTICA 131
POLYPHOR 132
REMPEX PHARMA 132
HIV 132
ATTACHMENT INHIBITORS 132
GENE MODIFICATION 133
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE 133
TABLE 93 INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY
DISEASE, 2015 133
CHAPTER 9 PATENT ANALYSIS 138
PATENT ANALYSIS 138
PATENT EXPIRATIONS 138
TABLE 94 U.S. PHARMACEUTICAL PATENT EXPIRY, 2010-2031 139
PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY,
DESCRIPTION AND APPROVAL DATE 140
TABLE 95 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, JAN.
2015 TO SEPT. 2015 140
PATENTS ISSUED BY COMPANY 148
TABLE 96 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PRODUCT
PATENTS BY COMPANY, JAN. 2015 TO SEPT. 2015 148
INFECTIOUS DISEASES PATENTS ISSUED, BY DISEASE 150
TABLE 97 PATENTS ISSUED FOR VACCINE AND TREATMENT OF INFECTIOUS
DISEASES BY DISEASE, JAN. 2015 TO SEPT. 2015 (NUMBER/%) 150
TABLE 98 INFECTIOUS DISEASES VACCINE AND PHARMACEUTICAL PATENTS BY
DISEASE ISSUED BETWEEN JAN. 2015 AND SEPT. 2015 (%) 151
CHAPTER 10 COMPANY DIRECTORY 153
ABBOTT LABORATORIES 153
BUSINESS OVERVIEW 153
TABLE 99 ABBOTT PHARMACEUTICAL PRODUCTS 153
PRODUCTS 153
TABLE 100 ABBOTT DIAGNOSTIC PRODUCTS 153
ABBVIE INC. 154
BUSINESS OVERVIEW 154
PRODUCTS 154
TABLE 101 ABBVIE PHARMACEUTICAL PRODUCTS 154
ALLERGAN (FORMERLY ACTAVIS) 154
BUSINESS OVERVIEW 155
PRODUCTS 155
TABLE 102 ALLERGAN PHARMACEUTICAL PRODUCTS 155
ALERE 155
BUSINESS OVERVIEW 155
PRODUCTS 156
TABLE 103 ALERE DIAGNOSTIC PRODUCTS 156
ALFA SCIENTIFIC DESIGNS 157
BUSINESS OVERVIEW 157
PRODUCTS 157
TABLE 104 ALFA SCIENTIFIC DESIGNS' DIAGNOSTIC PRODUCTS 157
ATLAS LINK BIOTECH CO. LTD. 157
BUSINESS OVERVIEW 158
PRODUCTS 158
TABLE 105 ATLAS LINK BIOTECH DIAGNOSTIC'S PRODUCTS 158
ASTRAZENECA 158
BUSINESS OVERVIEW 158
PRODUCTS 159
TABLE 106 ASTRAZENECA PHARMACEUTICAL'S PRODUCTS 159
AUROBIND PHARMA LTD. 159
BUSINESS OVERVIEW 159
BAXTER INTERNATIONAL INC. 159
BUSINESS OVERVIEW 160
PRODUCTS 160
TABLE 107 BAXTER PHARMACEUTICAL'S PRODUCTS 160
BAYER AG 160
BUSINESS OVERVIEW 160
PRODUCTS 160
TABLE 108 BAYER PHARMACEUTICAL'S PRODUCTS 160
BECTON DICKINSON 161
BUSINESS OVERVIEW 161
PRODUCTS 161
TABLE 109 BECTON DICKINSON DIAGNOSTIC'S PRODUCTS 161
BIO-RAD LABORATORIES 161
BUSINESS OVERVIEW 162
PRODUCTS 162
TABLE 110 BIO-RAD DIAGNOSTIC'S PRODUCTS 162
BOEHRINGER INGELHEIM GMBH 162
BUSINESS OVERVIEW 162
PRODUCTS 163
TABLE 111 BOEHRINGER INGELHEIM PHARMACEUTICAL'S PRODUCTS 163
BRISTOL-MYERS SQUIBB COMPANY 163
BUSINESS OVERVIEW 163
PRODUCTS 163
TABLE 112 BRISTOL-MYERS SQUIBB'S PHARMACEUTICAL PRODUCTS 163
CEPHEID 164
BUSINESS OVERVIEW 164
PRODUCTS 164
TABLE 113 CEPHEID DIAGNOSTIC'S PRODUCTS 164
CREATIVE PEPTIDES 164
BUSINESS OVERVIEW 165
PRODUCTS 165
TABLE 114 CREATIVE PEPTIDE'S DIAGNOSTIC PRODUCTS 165
CRUCELL NV 165
BUSINESS OVERVIEW 165
PRODUCTS 166
TABLE 115 CRUCELL'S VACCINE PRODUCTS 166
CUBIST PHARMACEUTICALS (SEE MERCK) 166
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC. 166
BUSINESS OVERVIEW 166
PRODUCTS 166
TABLE 116 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS' DIAGNOSTIC
PRODUCTS 166
DIASORIN 167
BUSINESS OVERVIEW 167
PRODUCTS 168
TABLE 117 DIASORIN DIAGNOSTIC'S PRODUCTS 168
FIRST DIAGNOSTIC CORP. 169
BUSINESS OVERVIEW 169
PRODUCTS 169
TABLE 118 FIRST DIAGNOSTIC'S PRODUCTS 169
FOCUS DIAGNOSTICS 169
BUSINESS OVERVIEW 170
PRODUCTS 170
TABLE 119 FOCUS DIAGNOSTIC'S PRODUCTS 170
FOREST LABORATORIES (SEE ALLERGAN) 170
GILEAD SCIENCES INC. 170
BUSINESS OVERVIEW 171
PRODUCTS 171
TABLE 120 GILEAD SCIENCE'S PHARMACEUTICAL PRODUCTS 171
GLAXOSMITHKLINE 171
BUSINESS OVERVIEW 171
PRODUCTS 172
TABLE 121 GLAXOSMITHKLINE PHARMACEUTICAL'S VACCINE PRODUCTS 172
HOLOGIC INC. 173
BUSINESS OVERVIEW 173
PRODUCTS 173
TABLE 122 HOLOGIC DIAGNOSTIC'S PRODUCTS 173
HOME ACCESS HEALTH CORP. 174
BUSINESS OVERVIEW 174
PRODUCTS 174
TABLE 123 HOME ACCESS HEALTH'S DIAGNOSTICS PRODUCTS 174
IDENIX PHARMACEUTICALS (SEE MERCK) 174
IMMUNOSTICS INC. 174
BUSINESS OVERVIEW 174
PRODUCTS 175
TABLE 124 IMMUNOSTIC'S DIAGNOSTIC PRODUCTS 175
JANSSEN THERAPEUTICS 175
BUSINESS OVERVIEW 175
PRODUCTS 175
TABLE 125 JANSSEN THERAPEUTIC'S PHARMACEUTICAL PRODUCTS 175
LUPIN PHARMACEUTICALS INC. 176
BUSINESS OVERVIEW 176
PRODUCTS 176
TABLE 126 LUPIN'S PHARMACEUTICAL PRODUCTS 176
MANGALAM DRUGS and ORGANICS LTD. 177
BUSINESS OVERVIEW 177
PRODUCTS 177
TABLE 127 MANGALAM'S PHARMACEUTICAL PRODUCTS 177

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Drug Discovery Outsourcing Global Market  – Forecast To 2022

Drug Discovery Outsourcing Global Market – Forecast To 2022

  • $ 15 000
  • Industry report
  • January 2016
  • by IQ4I Research & Consultancy Pvt. Ltd

Over the last two decades, the Pharmaceutical/Biotech industry has undergone radical changes. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards ...

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape

  • $ 4 995
  • Industry report
  • December 2015
  • by GBI Research

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape Summary Pancreatic Cancer (PC) is a disease predominately ...

Analysis of the Ethiopian Pharmaceutical Market 

Analysis of the Ethiopian Pharmaceutical Market 

  • $ 4 950
  • Industry report
  • January 2016
  • by Frost & Sullivan

Analysis of the Ethiopian Pharmaceutical Market : Market Position of Prescription and Over-the-counter Drugs This study offers an insight into the pharmaceutical industry of Ethiopia, where preference ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.